Skip to main content

Advertisement

SpringerLink
Log in

Biotherapy of chronic myelogenous leukemia

  • Review Article
  • Published:
Annals of Hematology Aims and scope Submit manuscript

Abstract

The aim of this review is to summarize the current knowledge on the clinical results of biotherapy of chronic myelogenous leukemia (CML) and potential mechanisms of the antitumor action of interferon alpha. IFN alpha treatment induces hematologic and cytogenetic remissions in patients with chronic phase CML. In addition, the duration of the chronic phase is prolonged by IFN alpha resulting in a significant survival benefit. In two randomized clinical trials this survival benefit was demonstrated in all chronic phase CML patients independent of their risk scores. Moreover, IFN treatment also delays the onset of clinical relapse after allogeneic bone marrow transplantation. The critical mechanisms of IFN action have not yet been identified. Both direct and indirect antiproliferative mechanisms have been described. In particular, differential regulation of growth promoting and growth inhibiting cytokines represents an attractive hypothetical mechanism of IFN action. Nevertheless, no leukemia specific IFN activities explaining cytogenetic remissions and/or delay of disease progression have been identified. Further research on that field are required to further improve biological CML therapies.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Alimena G, Brandt L, Dallapiccola B, Mitelman F, Nilsson PG (1979) Secondary chromosome changes in chronic myeloid leukemia. Cancer Genet Cytogenet 1:79–85

    Google Scholar 

  2. Alimena G, Meloni G, de Cuia MR, Rondinelli MB, Lo Coco F, Montefusco E, Mancini M, Pinto R, Nanni M, Cedrone M et al (1993) Management of chronic myeloid leukemia in chronic phase with autologous stem cell transplantation and alpha-2 interferon: cytogenetic and clinical results. Leuk Lymphoma 11 [Suppl 1]:281–291

    Google Scholar 

  3. Allan NC, Shepherd PCA, Richards SM (1994) Interferon alpha prolongs survival for patients with CML in chronic phase: preliminary results of the UK MRC randomized multicenter trial (abstract). Blood 84:382a (Abst 1513)

    Google Scholar 

  4. Aman MJ, Rudolf G, Goldschmitt J, Aulitzky WE, Lam C, Huber C, Peschel C (1993) Type-I interferons are potent inhibitors of interleukin-8 production in hematopoietic and bone marrow stromal cells. Blood 82:2371–2378

    PubMed  Google Scholar 

  5. Aman JM, Keller U, Derigs G, Mohammadzadeh M, Huber C, Peschel C (1994) Regulation of cytokine expression by interferon alpha in human bone marrow stroma cells: inhibition of hematopoietic growth factors and induction of IL-1 receptor antagonist. Blood (in press)

  6. Arcese W, Goldman JM, D'Arcangelo E, Schattenberg A, Nardi A, Apperley JF, Frassoni F, Aversa F, Prentice HG, Ljungman P et al (1993) Outcome for patients who relapse after allogenic bone marrow transplantation for chronic myeloid leukemia. Chronic Leukemia Working Party. European Bone Marrow Transplantation Group. Blood 82:3211–3219

    PubMed  Google Scholar 

  7. Aulitzky WE, Peschel C, Despres D, Aman J, Trautman P, Tilg H, Rudolf G, Huttmann H, Obermeier J, Herold M et al (1993) Divergent in vivo and in vitro antileukemic activity of recombinant interferon beta in patients with chronic-phase chronic myelogenous leukemia. Ann Hematol 67:205–211

    PubMed  Google Scholar 

  8. Barnett MJ, Eaves CJ, Phillips GL, Gascoyne RD, Hogge DE, Horsman DE, Humphries RK, Klingemann HG, Lansdorp PM, Nantel SH et al (1994) Autografting with cultured marrow in chronic myeloid leukemia: results of a pilot study [see comments]. Blood 84:724–732

    PubMed  Google Scholar 

  9. Ben-Neriah Y, Daley GQ, Mes-Masson AM, Witte ON, Baltimore D (1986) The chronic myelogenous leukemia-specific p210 protein is the product of the bcr-abl hybrid gene. Science 233:212–215

    PubMed  Google Scholar 

  10. Bi S, Lanza F, Goldman JM (1994) The involvement of “tumor suppressor” p53 in normal and chronic myelogenous leukemia hemopoiesis. Cancer Res 54:582–586

    PubMed  Google Scholar 

  11. Bortin MM, Horowitz MM, Rowlings PA, Rimm AA, Sobocinski KA, Zhang MJ, Gale RP (1993) 1993 progress report from the international bone marrow transplant registry. Bone Marrow Transplant 12:97–104

    PubMed  Google Scholar 

  12. Broustet A, Reiffers J, Marit G, Fiere D, Jaubert J, Reynaud J, Pris J, Bernard P, Charrin C, Wen ZQ et al (1991) Hydroxyurea versus interferon alfa-2b in chronic myelogenous leukaemia: preliminary results of an open French multicentre randomized study. Eur J Cancer 27 [Suppl 4]:S18–21

    Google Scholar 

  13. Broxmeyer HE, Lu E, Platzer E, Feit C, Juliano L, Rubin BY (1983) Comparative analyses of the influences of human gamma, alpha and beta interferons on human multipotential (CFU-GEMM), erythroid (BFU-E) and granulocyte macrophage (CFU-GM) progenitor cells. J Immunol 131:1300–1309

    PubMed  Google Scholar 

  14. Conlon KL, Urba WC, Smith JW, Steis RG, Longo DL, Clark SW (1990) Exacerbation of symptoms of autoimmune disease in patients receiving IFN alpha therapy. Cancer 65:2237–2242

    PubMed  Google Scholar 

  15. Derderian PM, Kantarjian HM, Talpaz M, O'Brien S, Cork A, Estey E, Pierce S, Keating M (1993) Chronic myelogenous leukemia in the lymphoid blastic phase: characteristics, treatment response, and prognosis. Am J Med 94:69–74

    PubMed  Google Scholar 

  16. Despres D, Goldschmitt J, Aulitzky WE, Huber C, Peschel C (1994) Differential effects of type-I interferon on hematopoietic progenitor cells: failure of IFN to inhibit IL-3-stimulated normal and CML progenitors. Exp Hematol (in press)

  17. Dowding C, Guo AP, Maisin D, Gordon MY, Goldman JM (1991) The effects of interferon-alpha on the proliferation of CML progenitor cells in vitro are not related to the precise position of the M-BCR breakpoint. Br J Haematol 77:165–171

    PubMed  Google Scholar 

  18. Dowding C, Guo AP, Osterholz J, Siczkowski M, Goldman J, Gordon M (1991) Interferon-alpha overrides the deficient adhesion of chronic myeloid leukemia primitive progenitor cells to bone marrow stromal cells. Blood 78:499–505

    PubMed  Google Scholar 

  19. Estrov Z, Markowitz AB, Kurzrock R, Wetzler M, Kantarjian HM, Ferrajoli A, Gutterman JU, Talpaz M (1993) Suppression of chronic myelogenous leukemia colony growth by interleukin-4. Leukemia 7:214–220

    PubMed  Google Scholar 

  20. Feinstein E, Cimino G, Gale RP, Canaani E (1992) Initiation and progression of chronic myelogenous leukemia. Leukemia [Suppl 1]:37–43

    Google Scholar 

  21. Failkow PJ, Jacobson RJ, Papayannopolou T (1977) Chronic myelocytic leukemia: clonal origin in a stem cell common to the granulocyte, erythrocyte platelet and monocyte/macrophage. Am J Med 63:125–134

    PubMed  Google Scholar 

  22. Fibbe WE, Gossenlink HM, van Eden G, van Damme J, Biliau A, Voogt PJ, Willemze R, Falkenburg JHF (1988) Proliferation of myeloid progenitor cells in human long-term bone marrow cultures is stimulated by interleukin-1 beta. Blood 72:1242–1255

    PubMed  Google Scholar 

  23. Freund M, von Wussow P, Dietrich H, Eisert R, Link H, Wilke H, Buchholz F, LeBlanc S, Fonatsch C, Deicher H et al (1989) Recombinant human Interferon (IFN)-alpha-2b in chronic myelogenous leukaemia: dose dependency of response and frequency of neutralizing anti-interferon antibodies. Br J Haematol 72:350–356

    PubMed  Google Scholar 

  24. Freund M, Hild G, Grote-Metke A, Nowak R, Otremba B, Wormann B, Koch O, Dohmen M, Kleine HD, Link H et al (1993) Combination of chemotheraphy and interferon-alpha-2b in the treatment of chronic myelogenous leukemia. Semin Hematol 30 [Suppl 1]:11–13

    PubMed  Google Scholar 

  25. Gaidano G, Serra A, Guerrasio A, Rege Cambrin G, Mazza U, Saglio G (1994) Genetic analysis of p53 and RB1 tumorsuppressor genes in blast crisis of chronic myeloid leukemia. Ann Hematol 68:3–7

    PubMed  Google Scholar 

  26. Galvani DW, Cawley JC (1989) Mechanism of action of alpha interferon in chronic granulocytic leukaemia: evidence for preferential inhibition of late progenitors. Br J Haematol 73:475–479

    PubMed  Google Scholar 

  27. Geissler D, Gastl G, Aulitzky W, Tilg H, Gaggl S, Konwalinka G, Huber C (1990) Recombinant interferon-alpha-2C in chronic myelogenous leukaemia: relationship of sensitivity of committed haematopoietic precursor cells in vitro (BFU-E, CFU-GM, CFU-Meg) and clinical response. Leuk Res 14:629–636

    PubMed  Google Scholar 

  28. Goldman JM (1992) Bone marrow transplantation for chronic myelogenous leukemia. Curr Opin Oncol 4:259–263

    PubMed  Google Scholar 

  29. Gordon MY, Dowding CR, Riley GP, Goldman JM, Greaves MF (1987) Altered adhesive interaction with bone marrow stroma of haematopoetic progenitor cells in chronic myelogenous leukemia. Nature 328:342–344

    PubMed  Google Scholar 

  30. Gordon MY, Atkinson J, Clarke D, Dowding CR, Goldman JM, Grimsley PG, Siczkowski M, Greaves MF (1991) Deficiency of a phosphatidylinositol-anchored cell adhesion molecule influences haemopoietic progenitor binding to marrow stroma in chronic myeloid leukaemia. Leukemia 5:693–698

    PubMed  Google Scholar 

  31. Gronthos S, To LB, Haylock DN, Juttner CA (1992) A differential sensitivity to recombinant human interferon-alpha-2a between normal and chronic myeloid leukaemic peripheral blood granulocyte-macrophage colony-forming units. Leuk Res 16:153–158

    PubMed  Google Scholar 

  32. Guilhot F (1993) Interferon-alpha and low-dose cytosine-arabinoside for the treatment of patients with chronic myelogenous leukemia in chronic phase. French CML Study Group. Semin Hematol 30:24–25

    PubMed  Google Scholar 

  33. Hehlmann R, Heimpel H, Hasford H et al (1994) Randomized comparison of interferon-alpha with busulfan and hydroxyurea in chronic myelogenous leukemia (Abstract). Blood 84:382a (Abst. 1512)

    Google Scholar 

  34. Hernandez JM, Gonzalez Sarmiento R, Martin C, Gonzalez M, Sanchez I, Corral J, Orfao A, Canizo MC, San Miguel JF, Lopez Borrasca A (1991) Immunophenotypic, genomic and clinical characteristics of blast crisis of chronic myelogenous leukaemia. Br J Haematol 79:408–414

    PubMed  Google Scholar 

  35. Herrmann F, Jonas D, Helfrich SG, Lindemann A, Schleiermacher E, Mertelsmann R (1990) Interferon-alpha-2c in chronic myelogenous leukemia (CML): hematologic, cytogenetic and molecular-genetic response of patients with chronic-phase CML previously resistant to therapy with interferongamma. Blut 61:226–231

    PubMed  Google Scholar 

  36. Hertenstein B, Wiesneth M, Novotny J, Bunjes D, Stefanic M, Heinze B, Huber G, Heimpel H, Arnold R (1993) Interferon-alpha and donor buffy coat transfusions for treatment of relapsed chronic myeloid leukemia after allogeneic bone marrow transplantation. Transplantation 56:1114–1118

    PubMed  Google Scholar 

  37. Higano CS, Raskind WH, Singer JW (1993) Use of interferon alpha-2a to treat hematologic relapse of chronic myelogenous leukemia after bone marrow transplantation. Acta Haematol 89 [Suppl 1]:8–14

    PubMed  Google Scholar 

  38. Hirsch Ginsberg C, LeMaistre AC, Kantarjian H, Talpaz M, Cork A, Freireich EJ, Trujillo JM, Lee MS, Stass SA (1990) RAS mutations are rare events in Philadelphia chromosome-negative/bcr gene rearrangement-negative chronic myelogenous leukemia, but are prevalent in chronic myelomonocytic leukemia. Blood 76:1214–1219

    PubMed  Google Scholar 

  39. Kanda Y, Shigano K, Nakao K, Yano M, Matsuo H (1994) Sudden hearing loss associated with interferon. Lancet 343:1134–1135

    PubMed  Google Scholar 

  40. Kantarjian HM, Keating MJ, Talpaz M (1987) Chronic myeloid leukemia in blast crisis: an analysis of 242 patients. Am J Med 83:445–454

    PubMed  Google Scholar 

  41. Kantarjian HM, Deisseroth A, Kurzrock R, Estrov Z, Talpaz M (1993) Chronic myelogenous leukemia: a concise update. Blood 82:691–703

    PubMed  Google Scholar 

  42. Klein H, Becher R, Lubbert M, Oster W, Schleiermacher E, Brach MA, Souza L, Lindemann A, Mertelsmann RH, Herrmann F (1990) Synthesis of granulocyte colony-stimulating factor and its requirement for terminal divisions in chronic myelogenous leukemia. J Exp Med 171:1785–1790

    PubMed  Google Scholar 

  43. Klingemann HG, Grigg AP, Wilkie Boyd K, Barnett MJ, Eaves AC, Reece DE, Shepherd JD, Phillips GL (1991) Treatment with recombinant interferon (alpha-2b) early after bone marrow transplantation in patients at high risk for relapse [corrected; published erratum appears in Bloo 1992 Jun 15; 79:3397]. Blood 78:3306–3311

    PubMed  Google Scholar 

  44. Kloke O (1993) Combination therapy for chronic myelogenous leukemia with interferon alpha and other cytokines. Semin Hematol 30:22–23

    Google Scholar 

  45. Kloke O, Niederle N, Qiu JY, Wandl U, Moritz T, Nagel Hiemke M, Hawig I, Opalka B, Seeber S, Becher R (1993) Impact of interferon alpha-induced cytogenetic improvement on survival in chronic myelogenous leukaemia. Br J Haematol 83:399–403

    PubMed  Google Scholar 

  46. Kolb HJ, Mittermuller J, Clemm C, Holler E, Ledderose G, Brehm G, Heim M, Wilmanns W (1990) Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood 76:2462–2465

    PubMed  Google Scholar 

  47. Kolb HJ, Mittermuller J, Hertenstein H, Schumm M, Holler E, de Witte T, Gunther W, Ljungman P, Goldman JM (1993) Adoptive immunotherapy in human and canine chimeras — the role of interferon alpha. EBMT Chronic Leukemia Working Party. Semin Hematol 30:37–39

    PubMed  Google Scholar 

  48. Konopka JB, Watanabe SM, Witte ON (1984) An alteration of the human c-abl protein in K562 cells unmasks associated tyrosine kinase activity. Cell 37:1035–1042

    PubMed  Google Scholar 

  49. Laneuville P, Sun G, Timm M, Vekemans M (1992) Clonal evolution in a myeloid cell line transformed to interleukin-3-independent growth by retroviral transduction and expression of p210bcr/abl. Blood 80:1788–1797

    PubMed  Google Scholar 

  50. Lo Coco F, Mandelli F, Diverio D, Alimena G, De Fabritiis P, Meloni G, Cedrone M, Frontani M, Guerrasio A, Saglio G (1990) Therapy-induced Ph1 suppression in chronic myeloid leukemia: molecular and cytogenetic studies in patients treated with alpha-2b IFN, high-dose chemotherapy and autologous stem cell infusion. Bone Marrow Transplant 6:253–258

    PubMed  Google Scholar 

  51. McWhirter JR, Wang JY (1991) Activation of tyrosinase ki-nase and microfilament-binding functions of c-abl by bcr sequences in bcr/abl fusion proteins. Mol Cell Biol 11:1553–1565

    PubMed  Google Scholar 

  52. McWhirter JR, Wang JY (1993) An actin-binding function contributes to transformation by the Bcr-Abl oncoprotein of Philadelphia chromosome-positive human leukemias. EMBO J 12:1533–1546

    PubMed  Google Scholar 

  53. Morra E, Alimena G, Lazzarino M, Liberati AM, Montefusco E, Bernasconi P, Mancini M, Donti E, Merante S, Dianzani F et al (1991) Evolving modalities of treatment with interferon alpha-2b for Ph1-positive chronic myelogenous leukaemia. Eur J Cancer 27 [Suppl 4]: S14–17

    PubMed  Google Scholar 

  54. Neubauer A, He M, Schmidt CA, Huhn D, Liu ET (1993) Genetic alterations in the p53 gene in the blast crisis of chronic myelogenous leukemia: analysis by polymerase chain reaction-based techniques. Leukemia 7:593–600

    PubMed  Google Scholar 

  55. Niederle N, Kloke O, Wandl UB, Becher R, Moritz T, Opalka B (1993) Long-term treatment of chronic myelogenous leukemia with different interferons: results from three studies. Leuk Lymphoma 9:111–119

    PubMed  Google Scholar 

  56. Niederwieser D, Arcese W, Bandini G, Schwaighofer H, Thaler J, Bosi A, Di Bartolomeo P, Alessandrino EP, Urban C, Gratwohl A (1993) Prophylactic use of interferon alpha after bone marrow transplantation for patients with chronic myelogenous leukemia at high risk of relapse: a pilot study. The Chronic Leukemia Working Party of the EBMT. Semin Hematol 30:40–43

    PubMed  Google Scholar 

  57. Nowell PC, Hungerford DA (1960) A minute chromosome in human granulocytic leukemia. Science 132:1497–1500

    Google Scholar 

  58. Ozer H, George SL, Schiffer CA, Rao K, Rao PN, Wurster Hill DH, Arthur DD, Powell B, Gottlieb A, Peterson BA et al (1993) Prolonged subcutaneous administration of recombinant alpha-2b interferon in patients with previously untreated Philadelphia chromosome-positive chronic-phase chronic myelogenous leukemia: effect on remission duration and survival: Cancer and Leukemia Group B study 8583. Blood 82:2975–2984

    PubMed  Google Scholar 

  59. Pendergast AM, Quilliam LA, Cripe LD, Bassing CH, Dai Z, Li N, Batzer A, Rabun KM, Der CJ, Schlessinger J et al (1993) BCR-ABL-induced oncogenesis is mediated by direct interaction with the SH2 domain of the GRB-2 adaptor protein. Cell 75:175–185

    PubMed  Google Scholar 

  60. Porter DL, Roth MS, McGarigle C, Ferrara JL, Antin JH (1994) Induction of graft-versus-host disease as immunotherapy for relapsed chronic myeloid leukemia. N Engl J Med 330:100–106

    PubMed  Google Scholar 

  61. Reiffers J, Montastruc M, Cahn JY, Souillet G, Troncy J, Leblond V, Caillot D, Troussard X, Marit G, Faberes C (1993) Autologous blood stem-cell transplantation and recombinant interferon alpha in chronic myeloid leukemia. Semin Hematol 30:51–52

    PubMed  Google Scholar 

  62. Rowley JD (1973) A new consistent chromosomal abnormality in chronic myelogenous leukemia identified by quinacrine fluorescence and Giemsa staining. Nature 243:290–293

    PubMed  Google Scholar 

  63. Russo D, Fanin R, Zuffa E, Damiani D, Gallizia C, Michieli M, Testoni N, Benfenati D, Visani G, Zaccaria A et al (1990) Sequential treatment of Ph-positive chronic myeloid leukemia with interferon gamma and interferon alpha. Haematologica (Pavia) 75:334–339

    Google Scholar 

  64. Sacchi S, Kantarjian HM, Cohen P et al (1994) Immune-mediated and unusual complications during interferon alpha therapy in chronic myelogenous leukemia (Abstract). Blood 84:150a (Abst. 587)

    Google Scholar 

  65. Shafik HM, Nokta MA, Pollard RB (1991) Recombinant interferon beta ser protects against zidovidine-induced genetic damage in AIDS patients. Antiviral Res 16:205–212

    PubMed  Google Scholar 

  66. Shepherd PC, Richards S, Allan NC (1994) Severe cytopenias associated with the sequential use of busulphan and interferon-alpha in chronic myeloid leukaemia. Br J Haematol 86:92–96

    PubMed  Google Scholar 

  67. Sullivan KM, Weiden PL, Storb R, Witherspoon RP, Fefer A, Fisher L, Buckner CD, Anasetti A, Appelbaum FR, Badger C et al (1989) Influence of acute and chronic graft-versus-host disease on relapse survival after bone marrow transplantation from HLA identical siblings as treatment of acute and chronic leukemia. Blood 73:1720–1728

    PubMed  Google Scholar 

  68. Talpaz M, McCredie KB, Trujillo J, Mavligit GM, Gutterman JU (1983) Leukocyte interferon induced myeloid cytoreduction in chronic myelogenous leukemia. Blood 62:689–692

    PubMed  Google Scholar 

  69. Talpaz M, Kantarjian HM, McCredie KB, Trujillo J, Gutterman JU (1987) Clinical investigation of human interferon alpha in chronic myelogenous leukemia. Blood 69:1280–1288

    PubMed  Google Scholar 

  70. Talpaz M, Kantarjian H, Kurzrock R, Trujillo JM, Gutterman JU (1991) Interferon-alpha produces sustained cytogenetic responses in chronic myelogenous leukemia Philadelphia chromosome-positive patients. Ann Intern Med 114:532–538

    PubMed  Google Scholar 

  71. Tauchi T, Boswell HS, Leibowitz D, Broxmeyer HE (1994) Coupling between p210bcr-abl and Shc and Grb2 adaptor proteins in hematopoietic cells permits growth factor receptor-independent link to ras activation pathway. J Exp Med 179:167–175

    PubMed  Google Scholar 

  72. Thaler J, Kuhr T, Gastl G, Huber H, Duba C, Kemmler G, Gattringer C, Fluckinger T, Niederwieser D, Seewann H et al (1991) Rekombinantes Interferon alpha-2c bei Phi-positiver chronischer myeloischer Leukämie. Dtsch Med Wochenschr 116:721–728

    PubMed  Google Scholar 

  73. Thaler J, Gastl G, Fluckinger T, Niederwieser D, Huber H, Seewann H, Silly H, Lang A, Abbrederis C, Gadner H et al (1993) Treatment of chronic myelogenous leukemia with interferon alpha-2c: response rate and toxicity in a phase-II multicenter study. The Austrian Biological Response Modifier (BRM) Study Group. Semin Hematol 30:17–19

    Google Scholar 

  74. The Italian Cooperative Study Group on Chronic Myeloid Leukemia (1992) A prospective comparison of alpha-IFN and conventional chemotherapy in Ph+ chronic myeloid leukemia. Clinical and cytogenetic results at 2 years in 322 patients. Haematologica (Pavia) 77:204–214

    Google Scholar 

  75. The Italian Cooperative Study Group on Chronic Myeloid Leukemia (1993) Evaluating survival after allogeneic bone marrow transplant for chronic myeloid leukemia in chronic phase: a comparison of transplant versus no-transplant in a cohort of 258 patients first seen in Italy between 1984 and 1986. Br J Haematol 85:292–299

    Google Scholar 

  76. Urbano-Ispizua A, Gill R, Matutes E, Levi S, Wiedemann LM, Catovsky D, Marshall CJ (1992) Low frequency of ras oncogene mutations in Philadelphia-positive acute leukemia and report of a novel mutation H61 Leu in a single case. Leukemia 6:342–346

    PubMed  Google Scholar 

  77. van Rhee F, Lin F, Cullis JO, Spencer A, Cross NC, Chase A, Garicochea B, Bungey J, Barrett J, Goldman JM (1994) Relapse of chronic myeloid leukemia after allogeneic bone marrow transplant: the case for giving donor leukocyte transfusions before the onset of hematologic relapse. Blood 83:3377–3383

    PubMed  Google Scholar 

  78. Wada C, Shionoya S, Fujino Y, Tokuhiro H, Akahoshi T, Uchida T, Ohtani H (1994) Genomic instability of microsatellite repeats and its association with the evolution of chronic myelogenous leukemia. Blood 83:3449–3456

    PubMed  Google Scholar 

  79. Wandl UB, Nagel Hiemke M, May D, Kreuzfelder E, Kloke O, Kranzhoff M, Seeber S, Niederle N (1992) Lupus-like autoimmune disease induced by interferon therapy for myeloproliferative discorders. Clin Immunol Immunopathol 65:70–74

    PubMed  Google Scholar 

  80. Wetzler M, Kurzrock R, Lowe DG, Kantarjian H, Gutterman JU, Talpaz M (1991) Alteration in bone marrow adherent layer growth factor expression: a novel mechanism of chronic myelogenous leukemia progression. Blood 78:2400–2406

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Hematology, Universitätsklinik Mainz, Langenbeckstrasse 1, D-55101, Mainz, Germany

    W. E. Aulitzky, C. Peschel, F. Schneller & C. Huber

Authors
  1. W. E. Aulitzky
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. C. Peschel
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. F. Schneller
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. C. Huber
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Aulitzky, W.E., Peschel, C., Schneller, F. et al. Biotherapy of chronic myelogenous leukemia. Ann Hematol 70, 113–120 (1995). https://doi.org/10.1007/BF01682030

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01682030

Key words

Search

Navigation